Latest research on Velcade

Bortezomib (originally PS-341 and marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.

Latest findings

Because of significant activity against multiple myeloma seen in Phase I trials [3], Phase II [31] and Phase III studies of PS-341 are being pursued or planned for use against multiple myeloma. [source, 2003]
Preclinical data in chronic lymphocytic leukemia have also been encouraging, and Phase II trials of PS-341 are being pursued to treat this disease as well. [source, 2003]
In Phase I studies of PS-341 as a single agent in patients with solid tumors, rare responses have been seen in cancers of the prostate, kidney, head and neck, and lung. [source, 2003]
Given its potential to enhance chemosensitivity, however, PS-341 is being combined with conventional agents in several ongoing Phase I studies. [source, 2003]
Similarly, a Phase I study of the combination of Doxorubicin and PS-341 is ongoing at the University of Wisconsin [32]. [source, 2003]
The combination of Paclitaxel and PS-341 is being studied at the Ohio State University (C Shapiro, personal communication). [source, 2003]
There are also currently ongoing Phase I trials of PS-341 in combination with 5-Fluorouracil [33], Irinotecan [34], and Gemcitabine [35]. [source, 2003]
Currently available drugs that most specifically target the ubiquitin-proteasome pathway, such as PS-341, focus predominantly on the proteasome itself. [source, 2003]
Agents such as the proteasome inhibitor PS-341 are already undergoing clinical trials, and data concerning the Phase I safety and Phase II efficacy of combinations with other antineoplastic agents will be forthcoming over the next several years. [source, 2003]
Targeting the 26S proteasome with the proteasome inhibitor bortezomib (Velcade, PS-341) is particularly effective in hematopoietic tumors. [source]